[3] European, American, Chinese, and Asian-Pacific regional headquarters are located respectively in respectively Hilden, Germany; Germantown, Maryland, United States; Shanghai, China; and Singapore.

[13] In 2011, QIAGEN acquired Ipsogen S.A. for US$101 million, adding to the company's product and IP portfolio in the blood cancer space.

[14] QIAGEN also acquired Cellestis Limited for US$374 million, giving the company access to QuantiFERON technology for disease detection and prevention.

The company announced a comprehensive restructuring program to focus on high-growth areas such as personalized medicine and business in emerging markets.

[30] In September 2020 QIAGEN announced the acquisition of Michigan-based NeuMoDx Inc. giving it two fully integrated systems for automated PCR.

[31] In May 2022, QIAGEN acquired the majority stake in BLIRT S.A., adding new R&D and manufacturing capabilities for customized and standardized recombinant enzymes, as well as molecular biology reagents.

[33] On March 3, 2020, Thermo Fisher Scientific announced plans for the acquisition of QIAGEN at €39 per share in cash, which valued the transaction at $11.5 billion at the time.

[34] The day after an open letter by hedge fund Davidson Kempner Capital Management, one of QIAGEN's largest shareholders, to reject the bid as undervalued,[35] Thermo Fisher raised their tender by 10% to €43 per share, an advance of $1B in value.

[37] Resulting from the failed takeover bid, QIAGEN announced it would buy the outstanding 80.1% of shares in NeuMoDx Molecular Inc., which it did not already own, for about $234 million.